Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Autor: Y. Escobar, Juan Carlos Adansa, Maria Jose Lecumberri, Pablo Luna, Begoña Muros, Jaime Feliu, Gerardo Cajaraville, Ana Blasco, M.V. Tornamira, Patricia del Barrio, María José Martínez, Pere Gascón, Rosa Alvarez, Virginia Calvo, Olatz Olariaga, Andrés Muñoz, Rafael López, María José Tamés, Joaquín Montalar, Juan Antonio Virizuela, Purificación Martínez
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: Supportive Care in Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
SUPPORTIVE CARE IN CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 1433-7339
0941-4355
Popis: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients' diary. Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.
All authors have declared no conflicts of interest. The research has been funded by Merck Sharp & Dohme (MSD). Merck Sharp & Dohme Spain-a subsidiary of Merck & Co. Inc., Whitehouse Station, New Jersey, USA-provided Financial Support for the conduct of the study.
Databáze: OpenAIRE
Externí odkaz: